Phase 1a Study
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease